BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
59.50
-1.52 (-2.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close61.02
Open61.51
Bid59.40 x 2900
Ask59.66 x 1400
Day's Range59.36 - 62.48
52 Week Range38.95 - 143.98
Volume1,192,972
Avg. Volume1,526,650
Market Cap3.311B
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Wall Street Has Given Up on These 2 Stocks, and That's a Huge Mistake
    Motley Fool

    Wall Street Has Given Up on These 2 Stocks, and That's a Huge Mistake

    For instance, Shopify (NYSE: SHOP) has been an expensive stock for years. StoneCo (NASDAQ: STNE) has unbelievably good numbers. In my mind, StoneCo is very similar to Square (NYSE: SQ), the fintech superstar in the U.S. Like Square, StoneCo is using technology to create a whole ecosystem of start-up retail entrepreneurs.

  • How bluebird bio (BLUE) Stock Stands Out in a Strong Industry
    Zacks

    How bluebird bio (BLUE) Stock Stands Out in a Strong Industry

    bluebird bio (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Repare and Forma Shares Gobbled Up in IPO
    GuruFocus.com

    Repare and Forma Shares Gobbled Up in IPO

    Both companies boosted price and number of shares in their offerings Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of BLUE.OQ earnings conference call or presentation 11-May-20 12:00pm GMT

    Q1 2020 bluebird bio Inc Earnings Call

  • Barrons.com

    Bluebird and Crispr Show Promise for Sickle-Cell Cures

    The new data on Crispr’s products prompts Canaccord Genuity analyst to raise her price target on the Buy-rated stock.

  • bluebird bio Reports Dramatic Improvement in Sickle Cell Patients with LentiGlobin Gene Therapy
    Motley Fool

    bluebird bio Reports Dramatic Improvement in Sickle Cell Patients with LentiGlobin Gene Therapy

    Patients in its clinical trial continue to be nearly free of the disease's most serious symptoms.

  • Better Buy: bluebird bio vs. Gilead Sciences
    Motley Fool

    Better Buy: bluebird bio vs. Gilead Sciences

    Gilead Sciences (NASDAQ: GILD) has been leading the hunt to find a treatment for COVID-19. As a result, shares of the company have performed well of late and are up by 18.7% since the year began. Meanwhile, bluebird bio (NASDAQ: BLUE), a biotech company that develops treatments for rare diseases, hasn't had the best of luck recently, with its shares down by 21.9% year to date.

  • Why Is Bluebird (BLUE) Up 17.4% Since Last Earnings Report?
    Zacks

    Why Is Bluebird (BLUE) Up 17.4% Since Last Earnings Report?

    Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Here is What Hedge Funds Think About bluebird bio Inc (BLUE)
    Insider Monkey

    Here is What Hedge Funds Think About bluebird bio Inc (BLUE)

    Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • bluebird bio's Shares March Higher, Can It Continue?
    Zacks

    bluebird bio's Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in bluebird bio.

  • Pliant Therapeutics Shares Have Climbed 44% Since This Week's IPO
    GuruFocus.com

    Pliant Therapeutics Shares Have Climbed 44% Since This Week's IPO

    Several other biotechs lined up to go public as life sciences companies gain higher profiles due to fight against the coronavirus Continue reading...

  • Barrons.com

    What Sanofi Might Buy With Its Regeneron Windfall

    The drug company has not said what it plans to do with the cash, but analysts speculate that it will pursue a gene therapy company worth around $5 billion.

  • Bluebird (BLUE) Upgraded to Buy: What Does It Mean for the Stock?
    Zacks

    Bluebird (BLUE) Upgraded to Buy: What Does It Mean for the Stock?

    Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”
    Motley Fool

    FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

    Between a string of avoidable problems and instability in the market, bluebird bio might be in for a rough decade.

  • GuruFocus.com

    8 Biotechs Tapping Secondary Markets for $3 Billion

    Company stocks drop on dilution, but monies could benefit shareholders down the line Continue reading...

  • Bluebird Prices New Shares At $55, Seeks To Raise $500 Million
    SmarterAnalyst

    Bluebird Prices New Shares At $55, Seeks To Raise $500 Million

    Bluebird Bio (BLUE) priced an offering of 9.09 million shares of its common stock at $55 each, the company said late on Monday.The gene therapy company, which expects the offering to close on May 21, seeks to raise gross proceeds of about $500 million from the sale. Shares in Bluebird were down 0.2% at $57 in Tuesday’s pre-market trading in the U.S. after plunging 34% year-to-date.Bluebird is also giving the underwriters a 30-day option to buy up to an additional 1.36 million shares in common stock. Goldman Sachs, BofA Securities and Cowen are acting as joint book-running managers of the offering.Last week, Bluebird announced that its partner Bristol-Myers Squibb Co. (BMY) will pay the company $200 million to buy out future royalty obligations of its two jointly developed cancer therapies ide-cel and bb21217.Five-star analyst Mark Breidenbach at Oppenheimer, maintained a Buy rating on the stock with a $111 price target, after meeting with Bluebird’s management.“FDA approval of ide-cel remains a top priority for both Bluebird and its partner Bristol-Myers Squibb, especially given BMY’s investment in trials aimed at future label expansions,” Breidenbach wrote in a note to investors. “We believe bb2121 has potential for rapid development in r/r MM, and we project its commercial approval in 2021.”Overall, Wall Street analysts are cautiously optimistic on the company’s stock. Out of 13 analysts, 10 have Buy ratings and 3 have issued Hold ratings adding up to a Moderate Buy consensus. The $99.73 average price target provides investors with 75% upside potential should the target be met in the next 12 months. (See Bluebird stock analysis on TipRanks)Related News: Bristol Myers to Pay Bluebird $200 Million in Royalties For Cancer Drugs Novavax Seeks To Raise $250 Million From Share Sale; Top Analyst Bumps Up PT AstraZeneca, Daiichi Get FDA Breakthrough Status For Gastro Cancer Drug More recent articles from Smarter Analyst: * Autodesk Earnings: Here’s What To Expect Today * Tilray To Shut Ontario Cannabis Greenhouse In Money-Saving Move * Here’s Why Roku Stock Will Stay Afloat * Is CymaBay’s Seladelpar Back in the Saddle? 5-Star Analyst Weighs In

  • MarketWatch

    Bluebird Bio's stock falls after proposed public stock offering

    Shares of Bluebird Bio Inc. fell 2.9% in premarket trading Monday, after the gene therapy company said it was proposing a public offering of $400 million worth of common stock. Based on Friday's stock closing price of $56.66, the offering could be for about 7.06 million shares, or about 12.7% of the current shares outstanding. All of the shares would be sold by the company. The stock has dropped 35.8% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has gained 7.9% and the S&P 500 has lost 15.0%.

  • bluebird (BLUE): Strong Industry, Solid Earnings Estimate Revisions
    Zacks

    bluebird (BLUE): Strong Industry, Solid Earnings Estimate Revisions

    bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • TheStreet.com

    Bristol-Myers, Bluebird Bio to Resubmit FDA Bid for Myeloma Treatment

    Bristol-Myers Squibb and Bluebird Bio say the FDA declined to move forward on the application for their experimental multiple myeloma treatment.

  • Better Buy: bluebird bio vs. Exelixis
    Motley Fool

    Better Buy: bluebird bio vs. Exelixis

    Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since the beginning of the year. With this backdrop in mind, it might be tempting to pick Exelixis as the better stock to buy.

  • MarketWatch

    Bluebird, Bristol-Myers Squibb have resubmit FDA bid for CAR-T therapy

    Shares of Bluebird Bio Inc. declined 5.9% in premarket trading on Wednesday after the company and Bristol-Myers Squibb Co. said the Food and Drug Administration had declined to move forward on the application for their experimental multiple myeloma treatment. Bristol's stock was down 0.1%. In a "refusal to file" letter, the regulatory agency reportedly cited issues with the manufacturing process. Bluebird and Bristol are seeking approval for idecabtagene vicleucel, a chimeric antigen receptor (CAR) T cell immunotherapy; Bristol Myers Squibb plans to resubmit the application in July. Under the terms of the co-development and co-promotion arrangement, the companies share equally in profits, and Bristol earlier this month paid Bluebird a $200 million upfront payment for a second CAR-T therapy in development. Bluebird is building a manufacturing plant in Durham, N.C., for the U.S. market. Since the start of the year, Bluebird's stock is down 35.2%, shares of Bristol have declined 1.3%, and the S&P 500 has tumbled 11.6%.

  • Barrons.com

    Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering

    This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.

  • Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
    Motley Fool

    Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

    The pharma giant and the smaller biotech will keep working together on a couple of promising CAR-T cancer therapies.

  • Reuters

    Bristol Myers to pay bluebird $200 million for future royalties on cancer therapies

    The treatments, ide-cel and bb21217, are part of a class of drugs called CAR-T therapies that involve drawing white blood cells from a patient, processing them to target cancer cells, and infusing them back into the patient. The companies will continue to equally share profits and losses in the United States, bluebird said. The company also said it was going to reduce the investment in building a U.S. commercial organization, and that its Chief Executive Officer Nick Leschly will decline nearly 100% of his salary for the next 12 months.

  • Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?